No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
VTGN VistaGen Therapeutics
- 2.5000
- +0.2500+11.11%
Close Dec 20 16:00 ET
- 2.6000
- +0.1000+4.00%
Post 19:43 ET
69.61MMarket Cap-3.38P/E (TTM)
2.5500High2.2300Low992.99KVolume2.2500Open2.2500Pre Close2.41MTurnover5.47%Turnover RatioLossP/E (Static)27.84MShares5.860052wk High0.75P/B45.40MFloat Cap2.220052wk Low--Dividend TTM18.16MShs Float1889.9991Historical High--Div YieldTTM14.22%Amplitude1.6200Historical Low2.4230Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
VistaGen Therapeutics Advances Neurocircuitry Treatments
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Vistagen to Present at the Stifel 2024 Healthcare Conference
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript Summary
VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Heat List
US
Overall
Symbol
Price
% Chg
No Data
